Needham Reiterates Buy on Blueprint Medicines, Maintains $130 Price Target
Blueprint Medicines Corp. +0.36% Pre
Blueprint Medicines Corp. BPMC | 82.77 82.77 | +0.36% 0.00% Pre |
Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:
BPMC) with a Buy and maintains $130 price target.